2017
DOI: 10.3389/fimmu.2017.01429
|View full text |Cite
|
Sign up to set email alerts
|

Butyrate Conditions Human Dendritic Cells to Prime Type 1 Regulatory T Cells via both Histone Deacetylase Inhibition and G Protein-Coupled Receptor 109A Signaling

Abstract: Recently, it has become clear that short-chain fatty acids (SCFAs), and in particular butyrate, have anti-inflammatory properties. Murine studies have shown that butyrate can promote regulatory T cells via the induction of tolerogenic dendritic cells (DCs). However, the effects of SCFAs on human DCs and how they affect their capacity to prime and polarize T-cell responses have not been addressed. Here, we report that butyrate suppresses LPS-induced maturation and metabolic reprogramming of human monocyte-deriv… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
138
0
3

Year Published

2019
2019
2022
2022

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 140 publications
(145 citation statements)
references
References 51 publications
4
138
0
3
Order By: Relevance
“…7 Based on the transcriptional profile of butyrate-treated LPS + IFN-c-matured DCs, we here find that butyrate treatment of moDC does not lead to an immunosuppressive phenotype as strong as PCF treatment. 7 Based on the transcriptional profile of butyrate-treated LPS + IFN-c-matured DCs, we here find that butyrate treatment of moDC does not lead to an immunosuppressive phenotype as strong as PCF treatment.…”
Section: Discussionmentioning
confidence: 62%
See 4 more Smart Citations
“…7 Based on the transcriptional profile of butyrate-treated LPS + IFN-c-matured DCs, we here find that butyrate treatment of moDC does not lead to an immunosuppressive phenotype as strong as PCF treatment. 7 Based on the transcriptional profile of butyrate-treated LPS + IFN-c-matured DCs, we here find that butyrate treatment of moDC does not lead to an immunosuppressive phenotype as strong as PCF treatment.…”
Section: Discussionmentioning
confidence: 62%
“…7 Based on the transcriptional profile of butyrate-treated LPS + IFN-c-matured DCs, we here find that butyrate treatment of moDC does not lead to an immunosuppressive phenotype as strong as PCF treatment. 36 However, as the IL-23 subunit IL12B is strongly down-regulated by butyrate, and IL-23 is a cardinal cytokine for Th17 amplification, we conclude that butyratetreated pro-inflammatory moDCs will hold a non-Th17polarizing phenotype, as also supported by Kaisar et al, 7 while promoting an innate based Type 17 environment. Although we identified a strong down-regulation of the IL12B, making it difficult to form the Th17-amplifying cytokine IL-23, other components of a Th17-polarizing phenotype are in play, e.g.…”
Section: Discussionmentioning
confidence: 62%
See 3 more Smart Citations